Skip to content

Precise and accurate diagnosis and treatment of hepatobiliary malignant tumor

Precise and accurate diagnosis and treatment of hepatobiliary malignant tumor

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800015008
Enrollment
Unknown
Registered
2018-02-28
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatobiliary malignant tumor

Interventions

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old male and female; 2. Hepatobiliary malignancy has undergone resection; 3. Histopathology or cytology confirmed as primary liver cancer or gallbladder malignancy; 4. No serious underlying diseases; 5. Have not previously treated with radiotherapy and chemotherapy; 6. No significant heart, lung, kidney dysfunction, no HIV or syphilis infection; 7. All patients should be signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Preoperative general poor, it is estimated can not tolerate surgery and postoperative chemotherapy and targeted therapy; 2.Combined with metastasis; unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, QT prolongation (> 450ms); 3. Other parts of malignant tumors emerged within the last 5 years; 4. Patients can not accept follow-up or are participating in other clinical trials; 5. The presence of drug abuse; or any medical, psychological or social condition that may affect research, instability of patient compliance, or even endanger the safety of the patient; 6. Conduct other experimental medications outside this study within 4 weeks prior to the study's initiation; or concurrently participate in another clinical study that may have an impact on the results of this study; 7. Mental or medical instability makes patients unwilling or unwilling to sign an informed consent form; 8. After comprehensive assessment, the researchers think that is not suitable for patients involved in this study.

Design outcomes

Primary

MeasureTime frame
Objective response rate;Progressive survival;

Secondary

MeasureTime frame
Overall survival;Disease control rate;Disease continue to reaction time;Five-year survival rate;Quality of life score;

Countries

China

Contacts

Public ContactZhao Haitao

Peking Union Medical College Hospital

pumchzht@aliyun.com+86 010-69156042

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026